A Type C teleconference was held today between eight members of the Division of Medical Imaging Products at the US FDA and Xemed’s regulatory advancement team. Prof. Bill Hersman, PhD, Sponsor of Xemed’s Hyperpolarized Xenon Investigational New Drug filing, had filed a request in April for this meeting. At the meeting Prof. Hersman presented Xemed’s regulatory advancement strategy, inviting FDA review and guidance.

The University of New Hampshire Office of Research Partnerships and Commercialization notified Xemed that a new patent is being added to Xemed’s intellectual property portfolio. UNH received notification that a US patent will issue on August 3, 2010 for their application “Spectral-Narrowing Diode Laser Array System”. Xemed LLC is exclusive licensee of patents awarded to the University of New Hampshire in hyperpolarized noble gas production technology.

The National Heart Lung and Blood Institute issued a Notice of Award to principal investigator Iulian C. Ruset, PhD regarding his grant entitled “Optimized whole-lung mapping of alveolar oxygen concentration using hyperpolarized xenon MRI.” This project is a collaboration between Xemed and the Center for in-vivo Hyperpolarized Gas MR Imaging at the University of Virginia, funded through the SBIR program as a Phase 2 project. Dr. Ruset is Director of Imaging Applications for Xemed LLC and will lead Xemed’s effort. G. Wilson Miller, PhD will lead the efforts of the University of Virginia team.

Xemed scientists coauthored twelve contributions to the scientific program of the International Society of Magnetic Resonance in Medicine, which began today in Stockholm, Sweden. Other coauthors on these contributions included scientists and clinicians from the University of New Hampshire, the University of Virginia, the Brigham and Women’s Hospital, Mirtech, Inc, and the Harvard School of Public Health.